Dolat Capital: JB Chemicals & Pharmaceuticals - Q1 Growth Driven By Cilacar And Nicardia
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
JB Chemicals and Pharmaceuticals Ltd. reported a strong Q1, led by 8.6% YoY growth in domestic formulations (11% QoQ despite a high base) versus Indian pharmaceutical market (IPM) de-growth of 5%.
The sharp growth was driven by cardiac portfolio (up 24%)– Cilacar and Nicardia as acute declined 1% YoY.
Exports (both formulations and active pharmaceutical ingredient) grew 28% YoY led by higher stocking. Improved product mix coupled with lower opex led Ebitda margins surge to 34% (up 980 basis points YoY).
Management expects to outperform IPM growth and sustenance in export growth in FY21E.
Further, it remains confident of its growth in the medium term led by newer launches in India, traction in contract manufacturing organization (CMO) and its export branded generics markets with sustenance of healthy Enitda margins at 20% plus.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.